Clinical Trial Search

Primary: Change From Baseline in the WOMAC Pain Score in the Target Knee at Week 26 [Western Ontario and McMaster Universities Arthritis Index (WOMAC®)] — -51.43; -54.49; -36.86…

Primary: Evaluation of Pain and Functional Performance Determined by the Harris Hip Score — 90.9 score on a scale

Primary: Change From Baseline to Part 2 in the Value of Muscle Fiber Area (MFA) % Comparing the Histology Biopsies Before and After 12 Months of Treatment With Givinostat…

Primary: Mean Number of Squamous Cell Carcinomas — 0.75; 1.00 # of squamous cell carcinomas — p=0.750

Primary: Veterans RAND-12 Mental Component Score (VR-12 MCS) — 36.82; 36.24; 37.25 score on a scale — p=<0.01

Primary: Number of Participants With a Composite Perinatal Outcome — 235; 261 Participants

Primary: Number of Participants With Abscess Resolution — 11; 9 Participants

Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) Total Letters Score at Month 1- Treated Eye — 0.132 logMAR

Primary: Mean Number of OZURDEX® Implant Reinjections in the Study Eye — 3.0 number of injections

Primary: Number of Subjects With Treatment-emergent Adverse Events (TEAEs) — 3; 11; 4; 4 Participants

Primary: Proportion of Participants With Treatment Response — 0.54; 0.71; 0.33 Proportion of participants — p=.03

Primary: Number of Participants Who Experience at Least 1 Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 4; 18; 6; 7 Participants

Primary: Measurement of Maximum Serum Concentration (Cmax) — 306.8; 214.9; 390.76; 286.49 ng/mL

Primary: Hepatic Fatty Acid Oxidation

Primary: Glycemic Response — 303; 306 mmol*120 min*l-1 — p=0.886